Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial

John R. Guyton, Sergio Fazio, Adeniyi J. Adewale, Erin Jensen, Joanne E. Tomassini, Arvind Shah, Andrew M. Tershakovec

    Research output: Contribution to journalArticle

    18 Scopus citations

    Abstract

    OBJECTIVE - To determine the effect of niacin on fasting glucose (FG) and new-onset diabetes in statin/ezetimibe-treated patients. RESEARCH DESIGN AND METHODS - This was a prespecified secondary analysis among 942 hyperlipidemic patients randomized to ezetimibe/simvastatin (E/S; 10/20 mg) or E/S + extended-release niacin (N; titrated to 2 g) over 64 weeks. RESULTS - FG levels peaked by 8-12 weeks, then declined even without antidiabetic medication. At 64 weeks, 3.5% taking E/S+N versus 2.6% taking E/S met criteria for new-onset diabetes (P = 0.66). An additional 1.4% taking E/S+N versus 0.4% taking E/S transiently met criteria for diabetes and then remitted (P = 0.46). Of 28 new-diabetes diagnoses in the E/S+N group, 25 occurred by 24 weeks. Among patientswith baseline diabetes, 13.9%taking E/S+N and 11.6% taking E/S underwent antidiabetic treatment modification. CONCLUSIONS - Increased FG and new-onset diabeteswith E/S+N occurred mainly around the time of initial uptitration of N and often improved or remitted without specific treatment.

    Original languageEnglish (US)
    Pages (from-to)857-860
    Number of pages4
    JournalDiabetes care
    Volume35
    Issue number4
    DOIs
    StatePublished - Apr 1 2012

    ASJC Scopus subject areas

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Advanced and Specialized Nursing

    Fingerprint Dive into the research topics of 'Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial'. Together they form a unique fingerprint.

  • Cite this